In patients with comorbid atopic dermatitis, elevated IgE levels were determining for first‐line prescription of dupilumab, whereas in patients without comorbid atopic dermatitis, elevated FeNO levels were the biomarker determinant. Here, IGHE is linked to atopic eczema.